Harbin Pharmaceutical Group Co (SHSE:600664) Net Income From Continuing Operations : ¥525 Mil (TTM As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Harbin Pharmaceutical Group Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Harbin Pharmaceutical Group Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥190 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥525 Mil.

Harbin Pharmaceutical Group Co Net Income From Continuing Operations Historical Data

The historical data trend for Harbin Pharmaceutical Group Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Pharmaceutical Group Co Net Income From Continuing Operations Chart

Harbin Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

121.87

-1,045.25

409.85

512.21

474.22

Harbin Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															139.99	81.36	126.81	126.06	190.31

Harbin Pharmaceutical Group Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥525 Mil.

Harbin Pharmaceutical Group Co (SHSE:600664) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Pharmaceutical Group Co Ltd (SHSE:600664) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

Xi'an Street West, People 's Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018

Website

http://www.hayao.com

Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.

Executives

Lin Guo Ren	senior management
Wang Hai Sheng	senior management
Liu Bo	senior management
Meng Xiao Dong	senior management
Xu Hai Ying	Directors, senior managers
Liang Chen	senior management
Wang Peng Hao	senior management
Xiao Qiang	senior management
Wei Shuang Ying	senior management
Zhou Xing	senior management
Bian Ke	Supervisors
Sha Mei	senior management
Jian Shi Hui Zhu Xi	Supervisors
Wang Zhi Fu	Supervisors
Jiang Lu	Director

Harbin Pharmaceutical Group Co (SHSE:600664) Headlines

No Headlines